What ₹1,699 Buys You — The Return Map to 2035

Before projecting forward, get the current situation exactly right. At ₹1,699 and 21× trailing earnings, Caplin is trading at a meaningful discount to both its own historical multiple range and the quality of business the numbers describe.

The P/E was 45–55× in 2015 on a smaller, less-proven business. Today it is 21× on a business that has delivered eleven years of execution, zero debt, 25%+ ROCE, and a USFDA-approved injectable facility. The multiple has compressed by 55–60% while the earnings base has grown 13×. That is the anomaly this return analysis is built on.

The stock price in 2035 is the product of two variables: what EPS will be, and what multiple the market assigns. The EPS trajectory is the more predictable of the two — it is anchored in business fundamentals. The multiple is the more volatile — it depends on market sentiment, sector re-rating, and how visible Caplin becomes as the US injectable story matures.

Four EPS scenarios, built on different growth rate assumptions. Bear uses 12% CAGR — roughly half the historical rate, implying significant deceleration. Base uses 20% — a meaningful slowdown from 33% but consistent with a maturing LatAm franchise plus early US contribution. Bull uses 28% — close to historical, implying US injectable ramp adds meaningfully to growth. Compounder uses 33% — historical continuation, requiring US + oncology + Africa all contributing by FY30.

Each scenario pairs an EPS estimate with a target multiple. The multiple assumption is as important as the EPS. At 21× today — a historically depressed level — even flat multiple expansion to 28–30× adds significant return on top of EPS growth. The scenarios below use conservative to optimistic multiple assumptions in each case.

The EPS scenarios above pair each growth rate with a "natural" multiple. But the multiple itself is independently powerful at current levels. Even if EPS growth slows to 20%, moving from 21× to 35× adds ~67% to the price on top of the earnings growth. This table isolates that effect — showing FY35 share price at every combination of EPS CAGR and exit multiple.

The highlighted row (30×) is the "fair value re-rate" — the multiple a business with this quality profile should trade at, not the distressed multiple it currently carries. Even the bear case EPS (12% CAGR) at a 30× multiple produces a 4.5× return in ten years. The floor is not the floor most investors think it is.

Assigning probabilities to scenarios is always subjective. These weights reflect the eleven-year execution track record, the quality of the moat, the management's demonstrated capital discipline, and the honest risks — geographic concentration, US execution uncertainty, currency exposure.

The probability-weighted expected return from ₹1,699 is approximately 12–13× over ten years — roughly 29% CAGR. That is the mathematical output of a business with this quality profile, at this multiple, with this runway, held for a decade.

For context: the Nifty 50 has delivered roughly 12–14% CAGR over the last decade. A fixed deposit delivers 6–7%. A 29% CAGR expected return — even probability-weighted across four scenarios including a bear case — is what you get when you buy a quality compounder at a distressed multiple and hold it through the compounding cycle.